Jushi Holdings (JUSHF) Cost of Revenue (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Cost of Revenue of $39.8 million for Q2 2026, up 10.09% year-over-year from $36.1 million in Q2 2025, and up 8.79% quarter-over-quarter from $36.6 million in Q1 2026.
Jushi Holdings (JUSHF) Cost of Revenue (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Cost of Revenue for 6 consecutive years, with $39.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cost of Revenue rose 10.09% year-over-year to $39.8 million; the TTM figure through Jun 2026 stood at $151.1 million (up 1.89% YoY), while the FY2025 annual figure was $148.9 million, up 6.97% from the prior year.
- Cost of Revenue improved to $39.8 million in Q2 2026 per JUSHF's latest filing, from $36.6 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $54.9 million in Q4 2022 and bottomed at $32.0 million in Q2 2024.
- Historically, Cost of Revenue has averaged $39.2 million across 5 years, with a median of $38.9 million in 2025.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 76.41% — and 2023, when it decreased 26.09%.
- Jushi Holdings' Cost of Revenue stood at $54.9 million in 2022, then declined by 26.09% to $40.6 million in 2023, then decreased by 0.24% to $40.5 million in 2024, then slipped by 1.8% to $39.7 million in 2025, then increased by 0.11% to $39.8 million in 2026.
- Business Quant data shows JUSHF's Cost of Revenue at $39.8 million in Q2 2026, $36.6 million in Q1 2026, and $39.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | 39.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.77 Mn |
| Jun 30, 2026 | 39.77 Mn |
| Mar 31, 2026 | 36.56 Mn |
| Mar 31, 2026 | 36.56 Mn |
| Dec 31, 2025 | 39.72 Mn |
| Dec 31, 2025 | 39.72 Mn |
| Sep 30, 2025 | 35.02 Mn |
| Sep 30, 2025 | 35.02 Mn |
| Jun 30, 2025 | 36.12 Mn |
| Jun 30, 2025 | 36.12 Mn |
| Mar 31, 2025 | 38.07 Mn |
| Mar 31, 2025 | 38.07 Mn |
| Dec 31, 2024 | 40.45 Mn |
| Dec 31, 2024 | 40.45 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Jun 30, 2024 | 32.03 Mn |
| Jun 30, 2024 | 32.03 Mn |
| Mar 31, 2024 | 33.13 Mn |
| Mar 31, 2024 | 33.13 Mn |